Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | APLNR | P35414 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21216586 | 1.00 | LMNA (0.40) | LMNACYP2C9SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL22964389 | 0.83 | LMNA (0.35) | LMNACYP2C9APLNR | |
| SCHEMBL10129912 | 0.79 | — | — | |
| SCHEMBL20692824 | 0.77 | — | — | |
| SCHEMBL13618680 | 0.76 | LMNA (0.39) | LMNACYP2C9SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL14298073 | 0.74 | LMNA (0.42) | LMNACYP2C9SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL8079753 | 0.74 | LMNA (0.42) | LMNACYP2C9SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL4743604 | 0.72 | LMNA (0.46) | LMNACYP2C9SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL26289641 | 0.72 | APLNR (0.31) | APLNR | |
| SCHEMBL22038223 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3743430-B1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20230041518-A1 | QUINOLINE DERIVATIVES | GILEAD SCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
| US-11116760-B2 | Quinoline derivatives | GILEAD SCIENCES, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-20200155538-A1 | QUINOLINE DERIVATIVES | GILEAD SCIENCES, INC. | 2020-05-21 | — | — | US | disclosed |
| US-20120028970-A1 | HETEROARYLTHIOMETHYL PYRIDINE DERIVATIVE | MSD K.K. (JP) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230041518-A1 | QUINOLINE DERIVATIVES | CFTR, NQO1, IRF3 | LMNA 2900/4885CYP2C9 823/4885SLC6A4 932/4885 |
| US-20200155538-A1 | QUINOLINE DERIVATIVES | CFTR, NQO1, IRF3 | LMNA 2900/4885CYP2C9 823/4885SLC6A4 932/4885 |
| US-20120028970-A1 | HETEROARYLTHIOMETHYL PYRIDINE DERIVATIVE | AR, NR5A1, ARL1 | LMNA 4077/4885CYP2C9 1044/4885SLC6A4 2369/4885 |
| US-11116760-B2 | Quinoline derivatives | CFTR, NQO1, IRF3 | LMNA 2900/4885CYP2C9 823/4885SLC6A4 932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.